Cellebrite DI Ltd. Class A Ordinary Shares
CLBTCellebrite DI Ltd. is a provider of digital intelligence solutions, specializing in data extraction, analysis, and management for law enforcement, intelligence agencies, and enterprise clients. Known for its technology that facilitates unlocking, decoding, and review of digital devices, the company supports investigations and cybersecurity efforts worldwide.
Company News
The article recommends three underappreciated growth stocks: Credo Technology (AI data center connectivity), Cellebrite (law enforcement digital evidence software), and TransMedics (organ transplant preservation technology). Each company is positioned in large, expanding markets with limited competition and strong fundamentals.
Cellebrite (NASDAQ: CLBT), a global leader in AI-powered digital investigative and intelligence solutions, announced the filing of its 2025 Annual Report on Form 20-F with the SEC. The report is available on the company's investor relations website and the SEC's website.
Portolan Capital increased its stake in Cellebrite by 1.4 million shares in Q3 2025, making it their 10th-largest holding. The investment firm appears confident in Cellebrite's digital intelligence solutions and potential for growth.
Cellebrite reported strong Q3 earnings, beating Wall Street expectations with $126.03 million in revenue and raising full-year guidance. The company saw nearly 18% year-over-year sales growth and anticipates further expansion through its pending Corellium acquisition.
Cellebrite reported strong Q2 2025 performance with 18% year-over-year revenue growth, exceeded earnings expectations, and appointed Tom Hogan as permanent CEO. The company remains cautiously optimistic about future business prospects and potential acquisition of Corellium.
